NCT07541053

Completed

Low Fat-free Mass in Prognosis of People With Chronic Obstru...

Mansoura University Source

Compare

Other study identifiers

Sponsor study identifier

MS.24.2.2706

Study Type

observational

Actual enrollment (reported)

90

Locations

1 country

Sites

1

Timeline

Study Start

April 1, 2024

Actual (reported)

Primary Completion

October 1, 2024

Actual (reported)

Study Completion

April 1, 2025

Actual (reported)

Brief Summary

The effects of low fat-free mass in Prognosis of people with chronic obstructive pulmonary disease (COPD) as regard clinical evaluation using BODE index, GOLD ABE assessment ( Gold 2024 ) functional evaluation using spirometry and 6 min walk test and radiological evaluation by computed chest tomography.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 90 participants
Study completion date: April 1, 2025
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
April 1, 2024
Actual (reported)
Primary Completion
October 1, 2024
Actual (reported)
Study Completion
April 1, 2025
Actual (reported)
First Submitted
April 15, 2026
Actual (reported)
First Posted
April 21, 2026
Actual (reported)

Last Updated: April 21, 2026
Status Verified: April 2026
Last Update Submitted: April 15, 2026

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Keywords

COPDFFMI

Outcome Measures

Primary Outcomes (1)

Fat-free Mass in Chronic Obstructive Pulmonary Disease
Functional evaluation using 6 min walk test distance (meter)
6 months

Study Arms (2)

Group A: COPD patients with low FFM

Defined as fat-free mass refers primarily to muscle mass, especially while considering body composition and weight management.

Group B : COPD patients with normal FFM

with normal or high FFM with matched age and sex to the patients group.

Eligibility Criteria

Age40 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

* Group A: COPD patients with low FFM which is defined as fat-free mass refers primarily to muscle mass, especially while considering body composition and weight management. * Group B: COPD patients with normal FFM with matched age and sex to the patients group.

You may qualify if:

Were adults aged ≥40 years with a clinical diagnosis of COPD confirmed by spirometry showing post-bronchodilator FEV₁/FVC \<0.70 according to GOLD 2024 criteria

Sponsors & Collaborators

Mansoura University
Otherlead

Study Sites (1)

Mansoura Univeristy Chest Medicine

Al Mansurah, Egypt

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Mohamed Abd ElMoniem
Lectruer of chest medicine
PRINCIPAL INVESTIGATOR

Enrollment

90 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: CROSS SECTIONAL
Target Duration: 3 Months
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Lecturer of chest medicine

Study Record Dates

First Submitted

April 15, 2026

First Posted

April 21, 2026

Study Start

April 1, 2024

Actual (reported)

NCT06503315

Genetic Polymorphism in Matrix Metalloproteinase 9 in Chronic Obstructive Pulmonary Disease in Sohag University Hospital.

Unknown

NCT06172946

Effect of Powerbreath Versus Transcutaneous Electrical Diaphragmatic Stimulation on The Severity of Copd

Not ApplicableCompleted

NCT06582082

Digital Health Integration With Pulmonary Rehabilitation on Patients With Chronic Obstructive Lung Disease

Not ApplicableCompleted

NCT05747235

The Role of Computed Tomography in the Phenotyping of COPD Patients

Completed

NCT05748977

Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients

Early Phase 1Unknown

NCT05448235

the Effectivness of the Thoracic Cage Mobilization on COPD Patients

Not ApplicableCompleted

You may not qualify if:

Exacerbation within the preceding month, active pulmonary infection, physical disability precluding study measurements (e.g., musculoskeletal or neurological disorders), advanced heart failure (NYHA class III-IV), malignancy or hyperthyroidism.

Contact the study team to confirm eligibility.

Primary Completion

October 1, 2024

Actual (reported)

Study Completion

April 1, 2025

Actual (reported)

Last Updated

April 21, 2026

Record last verified: 2026-04

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07541053
Data provider: ClinicalTrials.gov
Source updated: 2026-04-21
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:11 UTC

Locations

EG(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Group A: COPD patients with low FFM

Group B : COPD patients with normal FFM

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations